Background: Beneficial effects of probiotics have been reported for patients with allergic diseases and intestinal disorders. There is increasing interest in studying the role of different strains or combined probiotic administration on immunoregulation. In this study, we investigated whether probiotics modulate the immune response through regulating T cell proliferation and differentiation. Methods: We examined the effect of probiotic I (a combination of Lactobacillus acidophilus and Bifidobacterium bifidus) and probiotic II (a combination of L. acidophilus and B. infantis) on cell survival and proliferation, the progression of the cell cycle, and the production of Th1/Th2 cytokines by mitogen-stimulated murine spleen cells and human peripheral blood mononuclear cells (PBMCs). Results: Our experimental results showed that high concentrations (≧1 × 106 CFU/ml) of probiotic I or II inhibited mitogen-induced cell proliferation and arrested the cell cycle at the G0/G1 stage in both mitogen-stimulated spleen cells and PBMCs. In the results of low concentrations (<1 × 106 CFU/ml), probiotic I or II enhanced the production of IFN-γ but inhibited the production of IL-4. Our results indicated that high concentrations of probiotic I or II treatment could attenuate mitogen-induced overactive immune responses. On the other hand, low concentrations of probiotic I or II treatment could promote a shift in the Th1/Th2 balance toward Th1-skewed immunity. Conclusion: Dose selection is an important issue for probiotic studies. Our results indicated that probiotics have beneficial effects on regulating T cell-mediated immune responses by attenuating mitogen-induced overactive immune responses and promoting Th1 immune responses.

Keywords:
Probiotics, Lactobacillus, Bifidobacterium, T cell
1.
Dotan I, Rachmilewitz D: Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr Opin Gastroenterol 2005;21:426–430.
2.
Reiff C, Kelly D: Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol 2010;300:25–33.
3.
Gronlund MM, Lehtonen OP, Eerola E, Kero P: Fecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after cesarean delivery. J Pediatr Gastroenterol Nutr 1999;28:19–25.
4.
Nosova T, Jousimies-Somer H, Jokelainen K, Heine R, Salaspuro M: Acetaldehyde production and metabolism by human indigenous and probiotic Lactobacillus and Bifidobacterium strains. Alcohol Alcohol 2000;35:561–568.
5.
Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, Oh W: Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005;115:1–4.
6.
Reid G, Howard J, Gan BS: Can bacterial interference prevent infection? Trends Microbiol 2001;9:424–428.
7.
Coconnier MH, Bernet MF, Chauviere G, Servin AL: Adhering heat-killed human Lactobacillus acidophilus, strain LB, inhibits the process of pathogenicity of diarrhoeagenic bacteria in cultured human intestinal cells. J Diarrhoeal Dis Res 1993;11:235–242.
8.
Coconnier MH, Bernet MF, Kerneis S, Chauviere G, Fourniat J, Servin AL: Inhibition of adhesion of enteroinvasive pathogens to human intestinal caco-2 cells by Lactobacillus acidophilus strain lb decreases bacterial invasion. FEMS Microbiol Lett 1993;110:299–305.
9.
Schiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM, Donnet-Hughes A: Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 1995;78:491–497.
10.
Schiffrin EJ, Brassart D, Servin AL, Rochat F, Donnet-Hughes A: Immune modulation of blood leukocytes in humans by lactic acid bacteria: criteria for strain selection. Am J Clin Nutr 1997;66:515S–520S.
11.
Kailasapathy K, Chin J: Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol 2000;78:80–88.
12.
Bloksma N, de Heer E, van Dijk H, Willers JM: Adjuvanticity of lactobacilli. 1. Differential effects of viable and killed bacteria. Clin Exp Immunol 1979;37:367–375.
13.
Popova P, Guencheva G, Davidkova G, Bogdanov A, Pacelli E, Opalchenova G, Kutzarova T, Koychev C: Stimulating effect of DEODAN (an oral preparation from Lactobacillus bulgaricus ‘lb51’) on monocytes/macrophages and host resistance to experimental infections. Int J Immunopharmacol 1993;15:25–37.
14.
Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH: Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994;344:1046–1049.
15.
Miettinen M, Vuopio-Varkila J, Varkila K: Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 1996;64:5403–5405.
16.
Drakes M, Blanchard T, Czinn S: Bacterial probiotic modulation of dendritic cells. Infect Immun 2004;72:3299–3309.
17.
Zeuthen LH, Christensen HR, Frokiaer H: Lactic acid bacteria inducing a weak interleukin-12 and tumor necrosis factor alpha response in human dendritic cells inhibit strongly stimulating lactic acid bacteria but act synergistically with Gram-negative bacteria. Clin Vaccine Immunol 2006;13:365–375.
18.
Kanzato H, Fujiwara S, Ise W, Kaminogawa S, Sato R, Hachimura S: Lactobacillus acidophilus strain l-92 induces apoptosis of antigen-stimulated T cells by modulating dendritic cell function. Immunobiology 2008;213:399–408.
19.
Fanaro S, Chierici R, Guerrini P, Vigi V: Intestinal microflora in early infancy: composition and development. Acta Paediatr Suppl 2003;91:48–55.
20.
Mueller S, Saunier K, Hanisch C, Norin E, Alm L, Midtvedt T, Cresci A, Silvi S, Orpianesi C, Verdenelli MC, Clavel T, Koebnick C, Zunft HJ, Dore J, Blaut M: Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol 2006;72:1027–1033.
21.
Isolauri E, Sutas Y, Kankaanpaa P, Arvilommi H, Salminen S: Probiotics: effects on immunity. Am J Clin Nutr 2001;73:444S–450S.
22.
Ouwehand AC, Bergsma N, Parhiala R, Lahtinen S, Gueimonde M, Finne-Soveri H, Strandberg T, Pitkala K, Salminen S: Bifidobacterium microbiota and parameters of immune function in elderly subjects. FEMS Immunol Med Microbiol 2008;53:18–25.
23.
Okada Y, Tsuzuki Y, Hokari R, Komoto S, Kurihara C, Kawaguchi A, Nagao S, Miura S: Anti-inflammatory effects of the genus Bifidobacterium on macrophages by modification of phospho-i kappaB and SOCS gene expression. Int J Exp Pathol 2009;90:131–140.
24.
Nakanishi Y, Hosono A, Hiramatsu Y, Kimura T, Nakamura R, Kaminogawa S: Characteristic immune response in Peyer’s patch cells induced by oral administration of Bifidobacterium components. Cytotechnology 2005;47:69–77.
25.
Lopez P, Gueimonde M, Margolles A, Suarez A: Distinct bifidobacterium strains drive different immune responses in vitro. Int J Food Microbiol 2010;138:157–165.
26.
Kato I, Tanaka K, Yokokura T: Lactic acid bacterium potently induces the production of interleukin-12 and interferon-gamma by mouse splenocytes. Int J Immunopharmacol 1999;21:121–131.
27.
Borruel N, Carol M, Casellas F, Antolin M, de Lara F, Espin E, Naval J, Guarner F, Malagelada JR: Increased mucosal tumour necrosis factor alpha production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659–664.
28.
Van Deventer SJ: Tumour necrosis factor and Crohn’s disease. Gut 1997;40:443–448.
29.
Fiocchi C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182–205.
30.
Targan SR: Biology of inflammation in Crohn’s disease: mechanisms of action of anti-TNF-a therapy. Can J Gastroenterol 2000;14 Suppl C:13C–16C.
31.
Fang SH, Hwang LH, Chen DS, Chiang BL: Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 2000;33:791–798.
32.
Hovi T, Suni J, Hortling L, Vaheri A: Stimulation of chicken lymphocytes by T- and B-cell mitogens. Cell Immunol 1978;39:70–78.
33.
Toivanen P, Toivanen A: Selective activation of chicken T lymphocytes by concanavalin A. J Immunol 1973;111:1602–1603.
34.
Abbas AK, Lichtman AH, Pober JS: Cellular and Molecular Immunology, ed 2. Philadelphia, W.B. Saunders, 1994.
35.
Rao YK, Fang SH, Tzeng YM: Inhibitory effects of the flavonoids isolated from Waltheria indica on the production of NO, TNF-alpha and IL-12 in activated macrophages. Biol Pharm Bull 2005;28:912–915.
36.
Perdigon G, Maldonado Galdeano C, Valdez JC, Medici M: Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr 2002;56(suppl 4):S21–S26.
37.
Oelschlaeger TA: Mechanisms of probiotic actions – a review. Int J Med Microbiol 2010;300:57–62.
38.
Matsuzaki T, Chin J: Modulating immune responses with probiotic bacteria. Immunol Cell Biol 2000;78:67–73.
39.
Pohjavuori E, Viljanen M, Korpela R, Kuitunen M, Tiittanen M, Vaarala O, Savilahti E: Lactobacillus GG effect in increasing IFN-gamma production in infants with cow’s milk allergy. J Allergy Clin Immunol 2004;114:131–136.
40.
Gill HS, Rutherfurd KJ, Prasad J, Gopal PK: Enhancement of natural and acquired immunity by Lactobacillus rhamnosus (hn001), Lactobacillus acidophilus (hn017) and Bifidobacterium lactis (hn019). Br J Nutr 2000;83:167–176.
41.
Rafter JJ: The role of lactic acid bacteria in colon cancer prevention. Scand J Gastroenterol 1995;30:497–502.
42.
Sasaki T, Fukami S, Namioka S: Enhanced resistance of mice to Escherichia coli infection induced by administration of peptidoglycan derived from Bifidobacterium thermophilum. J Vet Med Sci 1994;56:433–437.
43.
Sasaki T, Fukami S, Namioka S: Enhancement of cytotoxic activity of lymphocytes in mice by oral administration of peptidoglycan (PG) derived from Bifidobacterium thermophilum. J Vet Med Sci 1994;56:1129–1133.
44.
Sekine K, Ohta J, Onishi M, Tatsuki T, Shimokawa Y, Toida T, Kawashima T, Hashimoto Y: Analysis of antitumor properties of effector cells stimulated with a cell wall preparation (WPG) of Bifidobacterium infantis. Biol Pharm Bull 1995;18:148–153.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.